Cutler Group LP Fibrogen Inc Put Options Transaction History

Cutler Group LP

16 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2023 Jul 18, 2023	BUY	$2.49 - $20.59 $96,363 - $796,833	38,700 Added 6450.0%	39,300 $65,000
Q1 2022 Apr 14, 2022	SELL	$12.02 - $16.79 $12,020 - $16,790	-1,000 Reduced 62.5%	600 $9,000
Q4 2021 Jan 18, 2022	SELL	$9.93 - $15.39 $23,832 - $36,936	-2,400 Reduced 60.0%	1,600 $26,000
Q3 2021 Oct 26, 2021	BUY	$10.18 - $26.64 $30,540 - $79,920	3,000 Added 300.0%	4,000 $34,000
Q2 2021 Jul 19, 2021	BUY	$18.57 - $35.68 $18,570 - $35,680	1,000 New	1,000 $3,000
Q1 2021 Apr 26, 2021	SELL	$31.0 - $55.72 $15,500 - $27,860	-500 Closed	0 $0
Q2 2020 Jul 22, 2020	SELL	$32.57 - $42.83 $91,196 - $119,924	-2,800 Reduced 84.85%	500 $1,000
Q1 2020 May 07, 2020	SELL	$23.3 - $45.96 $239,990 - $473,388	-10,300 Reduced 75.74%	3,300 $21,000
Q4 2019 Feb 06, 2020	BUY	$34.58 - $48.06 $411,502 - $571,914	11,900 Added 700.0%	13,600 $40,000
Q3 2019 Oct 28, 2019	BUY	$36.98 - $48.45 $7,395 - $9,690	200 Added 13.33%	1,700 $7,000
Q2 2019 Aug 09, 2019	SELL	$35.13 - $55.53 $175,650 - $277,650	-5,000 Reduced 76.92%	1,500 $3,000
Q1 2019 May 10, 2019	BUY	$42.83 - $59.91 $222,716 - $311,532	5,200 Added 400.0%	6,500 $13,000
Q4 2018 Feb 05, 2019	SELL	$37.97 - $60.16 $11,391 - $18,048	-300 Reduced 18.75%	1,300 $15,000
Q2 2018 Aug 10, 2018	SELL	$44.9 - $64.95 $731,870 - $1.06 Million	-16,300 Reduced 91.06%	1,600 $0
Q4 2017 Jan 17, 2018	SELL	$41.95 - $60.1 $1.82 Million - $2.61 Million	-43,500 Reduced 70.85%	17,900 $14,000
Q3 2017 Oct 17, 2017	BUY	$33.4 - $53.9 $2.05 Million - $3.31 Million	61,400	61,400 $83,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.